Drug alert: 14 out of 1204 samples declared as NSQ in February 2021

The manufacturers of these drugs are based in Uttarakhand, Telangana, Delhi, Himachal Pradesh, Bengaluru and Uttar Pradesh.

196
Laboratory test chemical
Picture: Pixabay

Last Updated on March 24, 2021 by The Health Master

Drug alert: 14 out of 1204 samples declared as NSQ in February 2021

The Central Drugs Standard Control Organisation (CDSCO) has declared 1,190 as standard quality (SQ) based on testing done on 1,204 samples in the month of February 2021.

However, it concluded that there were only 14 samples which were declared as not of standard quality (NSQ).

For detailed NSQ list, click here

The manufacturers of these drugs are based in Uttarakhand, Telangana, Delhi, Himachal Pradesh, Bengaluru and Uttar Pradesh.

Laboratory
Picture: Pixabay

The 14 NSQ drugs include

Ulgel – A 200 ml (magaldrate, simethicone & oxetacaine oral suspension) manufactured by Alembic Pharmaceuticals Ltd, South Sikkim failed the test of assay of oxetacaine.

Delsone-M 16 tablets (methylprednisolone tablets IP 16 mg) manufactured by Psychotropics India Ltd, Uttarakhand which failed the test of dissolution.

Amoxycillin & potassium clavulanate tablets IP 625 mg manufactured by Stride Organics Private Ltd, Uttarakhand for failing the test of dissolution & assay of potassium clavulanate.

Cardirid (carvedilol tablets IP) manufactured by Ridley Life Science Pvt. Ltd, Delhi failed the test of uniformity of content and related substances.


Also read:

FAQs – on Blood Pressure Monitoring Devices

Indian pharma firm develops Oral vaccine in capsule form for C-19…

Pharma Paint Launches Antiviral Paint: Must Read

5 technology trends in the Pharma & Medical Industry: Must read

Pharma Industry seeks clarity on Methylcobalamin ban


Ramze-5 (ramipril tablets IP) manufactured by Zee Laboratories, Himachal Pradesh which failed the test of assay.

Theopenam -1g (meropenem injection IP) manufactured by Theon Pharmaceuticals, Himachal Pradesh for failing the test of particulate matter and clarity of solution.

Rosuvas 20 (rosuvastatin tablets IP) manufactured by Sun Pharma Laboratories, East-Sikkim failed the test of uniformity of weight, dissolution and assay based on analysis done by Central Drugs Laboratory (CDL), Kolkata.

Amoxycillin capsules IP 500 mg manufactured by Yeluri Formulations Pvt. Ltd, Telangana for failing the test of assay.

Doxylamine succinate & pyridoxine hydrochloride tablets manufactured by Cure Healthcare Pvt. Ltd, Uttarakhand which failed the test of disintegration time.

Prolonged-release diltiazem tablets BP 90mg manufactured by Skymap Pharmaceuticals, Uttarakhand failed the test of dissolution.

To read more about Govt Laboratories, click here

Revol-CC (calcium carbonate magnesium oxide, manganese sulphate, zinc vitamin D3 tablets) manufactured by Mascot Health, Uttarakhand for failing the test of assay of vitamin D3.

Aspirin gastro-resistant tablets IP 150 mg manufactured by Unicure India Ltd, Uttar Pradesh which failed the test of test for salicylic acid based on analysis done by Central Drugs Testing Laboratory (CDTL), Mumbai.

Ciprofloxacin hydrochloride tablets IP 500 mg manufactured by Karnataka Antibiotics & Pharmaceuticals Limited; Bengaluru failed the test of dissolution.

Cefpodoxime proxetil dispersible tablets (brotocef-100 DT tablets) manufactured by J.M. Laboratories, Himachal Pradesh which failed the test of assay based on analysis done by Regional Drugs Testing Laboratory (RDTL), Chandigarh.


Other related news:

Drug alert: 16 out of 1001 samples declared as NSQ in January 2021: CDSCO

15 samples out of 943 declared as NSQ in December: CDSCO

14 samples out of 746 declared as NSQ in Nov 2020: CDSCO

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner